No recommendations so far.What's your call on Cadila Health today? Read 3 investor views
|Company Name||Last Price||%
|Dr Reddys Labs||2539.35||-1.48||2939.80||1904.15||43,196.60|
|Mar' 14||Dec' 13||Sep' 13||Jun' 13|
|Scheme||No. of Shares|
|Reliance Pharma Fund (G)||781,048|
|Reliance Equity Opportunities Fund - Retail Plan (G)||541,297|
|DSP BlackRock Top 100 Equity Fund - Regular Plan (G)||370,842|
|Reliance Regular Savings Fund - Equity Option (G)||360,377|
Cadila Health is in the Pharmaceuticals sector. The current market capitalisation stands at Rs 19,924.08 crore.The company has reported a consolidated sales of Rs 1,838.04 crore and a Net Profit of Rs 195.19 crore for the quarter ended Dec 2013.
The company management includes Pankaj R Patel - Chairman & Managing Director, Sharvil P Patel - Deputy Managing Director, Humayun Dhanrajgir - Director, Mukesh M Patel - Director, Nitin R Desai - Director, Apurva S Diwanji - Director.
It is listed on the BSE with a BSE Code of 532321 and the NSE with an NSE Code of CADILAHC.
Its Registered office is at "Zydus Tower", Satellite Cross Roads,,Sarkhej Gandhinagar Highway Ahmedabad,Gujarat - 380015.
Their Registrars are Sharepro Services (India) Pvt.Ltd.